Sirtex

Sydney, Australia Founded: 1991 • Age: 35 yrs Acquired By CDH
Radiation therapy for cancer treatment is developed and provided.
Request Access

About Sirtex

Sirtex is a company based in Sydney (Australia) founded in 1991 was acquired by CDH in June 2018. It operates as a Direct-to-Consumer (D2C), and Professional Services. Sirtex has completed 1 acquisition, including OncoSec Medical. Sirtex offers products and services including SIR-Spheres Y-90 Resin Microspheres, LAVA Liquid Embolic System, and SIROS INSYTE with SurePlan LiverY90. Sirtex operates in a competitive market with competitors including RefleXion, Alpha Tau Medical, Mevion Medical Systems, ZAP-X and ABK Biomedical, among others.

  • Headquarter Sydney, Australia
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Sirtex Medical Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Sirtex

Sirtex offers a comprehensive portfolio of products and services, including SIR-Spheres Y-90 Resin Microspheres, LAVA Liquid Embolic System, and SIROS INSYTE with SurePlan LiverY90. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Used for treating unresectable liver tumors and metastases.

Designed for embolization in various medical treatment procedures.

Supports planning and delivery of liver cancer treatments.

People of Sirtex
Headcount 200-500
Employee Profiles 80
Employee Profiles
People
Jeffrey Cyr
Vice President Of Regulatory Affairs & Quality Assurance
People
Francis Jannot
Executive Vice President International Commercial
People
Antoine Lecourt
Senior Director Of EMEA Marketing
People
Catherine W. Parham
Chief Medical Officer & EVP of Research & Development

Unlock access to complete

Funding Insights of Sirtex

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Sirtex

Sirtex has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include China Grand Pharmaceutical and Healthcare and CDH. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Private equity and private debt firm focused on multiple sectors
Founded Year Domain Location
Finished formulations and APIs are manufactured for therapeutic categories.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Sirtex

Sirtex has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include OncoSec Medical. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Intratumoral immunotherapies are developed to harness immune responses against cancer.
2011
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Sirtex

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Sirtex Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Sirtex

Sirtex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as RefleXion, Alpha Tau Medical, Mevion Medical Systems, ZAP-X and ABK Biomedical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Biology-guided radiotherapy systems are provided for cancer treatment.
domain founded_year HQ Location
Radiotherapy technique for solid tumors is developed using alpha-emitting seeds.
domain founded_year HQ Location
Proton therapy systems are supplied for cancer radiation treatment.
domain founded_year HQ Location
Developer of gyroscopic radiosurgery platform
domain founded_year HQ Location
Imageable embolic devices are developed for hypervascular tumors.
domain founded_year HQ Location
Targeted radiopharmaceuticals are developed for solid tumor treatment.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Sirtex

When was Sirtex founded?

Sirtex was founded in 1991.

Where is Sirtex located?

Sirtex is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.

What does Sirtex do?

Sirtex is focused on the development and distribution of innovative medical devices for the treatment of liver cancer and related conditions. The company specializes in products like SIR-Spheres Y-90 Resin Microspheres for treating unresectable liver tumors and metastases, alongside other solutions such as the LAVA Liquid Embolic System for embolization procedures. Operating in the healthcare sector, Sirtex serves professionals and patients globally through offices in the United States, Australia, Germany, and Singapore. Their offerings are tailored to address critical needs in oncology, providing targeted therapies and support for complex medical challenges.

Who are the top competitors of Sirtex?

Sirtex's top competitors include RefleXion, Alpha Tau Medical and Starget Pharma.

What products or services does Sirtex offer?

Sirtex offers SIR-Spheres Y-90 Resin Microspheres, LAVA Liquid Embolic System, and SIROS INSYTE with SurePlan LiverY90.

How many acquisitions has Sirtex made?

Sirtex has made 1 acquisition, including OncoSec Medical.

Who are Sirtex's investors?

Sirtex has 2 investors. Key investors include China Grand Pharmaceutical and Healthcare, and CDH.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available